First Line Osimertinib in the Real World: an Inter-regional Prospective Study
NCT04965701
·
clinicaltrials.gov ↗
COMPLETED
Status
200
Enrollment
OTHER
Sponsor class
Conditions
EGF-R Positive Non-Small Cell Lung Cancer
Interventions
DRUG:
Osimertinib 80 MG
Sponsor
Istituto Oncologico Veneto IRCCS